The FDA Just Approved the First Generic Nasal Spray to Reverse Opioid Overdoses

Time | April 19, 2019

The FDA Just Approved the First Generic Nasal Spray to Reverse Opioid Overdoses
The Food and Drug Administration (FDA) on Friday announced that it granted final approval to the first generic naloxone hydrochloride nasal spray, which can be used to reverse opioid overdoses. The approval is part of the FDA’s wider effort to make tools for stopping or preventing opioid overdoses more accessible and widely used. The agency is also working with drug companies to bring over-the-counter versions of naloxone to market, and is prioritizing the approval of other generic naloxone products. Friday’s announcement, which makes official a tentative approval previously granted to Teva Pharmaceuticals, means there will soon be a generic alternative to Narcan, the widely used naloxone nasal spray sold by Emergent BioSolutions.

Spotlight

In this infographic you will learn about the biggest challenges that are facing those using data analytics in their drug development, the strengths of using AI & Machine Learning, how the use of Real World Data can be improved and where the future lies in data analytics in pharma development with many more insights.

Related News

PHARMACY MARKET

AstraZeneca and R-Pharm sign an agreement to cooperate on COVID-19 vaccine development

AstraZeneca | December 22, 2020

The Russian Direct Investment Fund (RDIF, Russia's sovereign abundance reserve), The Gamaleya National Center, AstraZeneca and R-Pharm have consented to an arrangement focused on the turn of events and usage of a clinical exploration program to survey the immunogenicity and security of the consolidated utilization of one of the segments of the Sputnik V immunization created by the Gamaleya Center, and one of the segments of the AZD1222 antibody, created by AstraZeneca and the University of Oxford. The arrangement was declared on a video-gathering with Vladimir Putin, the President of Russia. The gatherings have likewise consented to create logical and business relations and investigate the opportunities for joint utilization of the Sputnik V antibody and the AZD1222 antibody to make more viable and long haul inoculation against potential new Covid diseases. Clinical preliminaries of the mix of AZD1222 antibody with Sputnik V's human adenoviral vector type Ad26 will start soon. R-Pharm will be among the associations financing the preliminary. Sputnik V is among the world's best and safe immunizations because of its novel innovation consolidating two diverse human adenoviral vectors accommodating a more grounded and longer-term resistant reaction contrasted with antibodies utilizing similar part for the two vaccinations. The routine with two distinctive adenoviral vectors for a prime and a lift vaccination is an extraordinary and momentous disclosure of the Gamaleya Center researchers. It serves to totally dodge invulnerability to the main vector, which is shaped after the principal vaccination, and hence to raise adequacy and make long haul resistance. This routine is one reason why the antibody shows viability of over 90%, with 100% adequacy in serious cases. Among the main COVID-19 antibodies just Sputnik V is utilizing the two-vector innovation.

Read More

PHARMA TECH

Phio Pharmaceuticals Announces Three Poster Presentations at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Phio Pharmaceuticals Corp | October 26, 2020

Phio Pharmaceuticals Corp. a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced three upcoming poster presentations discussing INTASYL compounds, including posters being delivered by two development partners, AgonOx, Inc. and the Helmholtz Zentrum München, at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020), to be held virtually from November 9-14, 2020.

Read More

New AMR Action Fund steps in to save collapsing antibiotic pipeline with pharmaceutical industry investment of US$1 billion

AMR Action Fund | July 09, 2020

Today, more than 20 leading biopharmaceutical companies announced the launch of the AMR Action Fund, a ground-breaking partnership that aims to bring 2-4 new antibiotics to patients by 2030. These treatments are urgently needed to address the rapid rise of antibiotic-resistant infections – also called antimicrobial resistance, or AMR. The companies have raised so far nearly US$1 billion new funding to support clinical research of innovative new antibiotics that are addressing the most resistant bacteria and life-threatening infections. Through the AMR Action Fund, pharmaceutical companies will join forces with philanthropies, development banks, and multilateral organizations to strengthen and accelerate antibiotic development. The Fund will focus on urgent public health needs. It will provide much needed financial resources, as well as important technical support to help biotech companies bring novel antibiotics to patients. The AMR Action Fund, an initiative of the international body representing the R&D pharmaceutical industry (International Federation of Pharmaceutical Manufacturers & Associations, IFPMA), was announced at simultaneous virtual launch events in Berlin, Germany, and Washington, D.C., USA, with a third event in Tokyo, Japan taking place on July 10.

Read More

Spotlight

In this infographic you will learn about the biggest challenges that are facing those using data analytics in their drug development, the strengths of using AI & Machine Learning, how the use of Real World Data can be improved and where the future lies in data analytics in pharma development with many more insights.